Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRMakoto Maemondo, Toshihiro Nukiwa, Toshiyuki Harada et al.|New England Journal of Medicine|2010Cited by 5.6k
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trialHaruhiro Saito, Makoto Maemondo, Tatsuro Fukuhara et al.|The Lancet Oncology|2019Cited by 636
First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for ChemotherapyAkira Inoue, Koichi Hagiwara, Kunihiko Kobayashi et al.|Journal of Clinical Oncology|2009Cited by 516
Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene MutationsAkira Inoue, Toshihiro Nukiwa, Takuji Suzuki et al.|Journal of Clinical Oncology|2006Cited by 504
Severe acute interstitial pneumonia and gefitinibAkira Inoue, Toshihiro Nukiwa, Yasuo Saijo et al.|The Lancet|2003Cited by 456